Clinical cancer research 2002: new agents and therapies.
The American Society of Clinical Oncology (ASCO) held its 38th annual meeting in Orlando, Florida on 17-22 May 2002. Leading oncologists in several subspecialties shared their expertise in nearly 200 educational sessions, and researchers reported the latest clinical cancer advances in more than 1800 abstract presentations. This review will focus on several new rationally designed agents and therapies with drugs directed at the epidermal growth factor (EGF) or its downstream pathway, farnesyltransferase and MAPK/ERK/kinase inhibition, and anti-angiogenesis drugs. Presented data at the ASCO-meeting are reviewed and placed into perspective.
Gietema
J A
JA
Department of Medical Oncology, University Hospital Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands. j.a.gietema@int.azg.nl
de Vries
E G E
EG
D000818:Animals; D035843:Biomedical Research; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data* / Q000639:trends; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy
D004791:Enzyme Inhibitors; D004815:Epidermal Growth Factor